Royalty Pharma plc (RPRX) is a Biotechnology company in the Healthcare sector, currently trading at $48.82. It has a SharesGrow Score of 72/100, indicating a above average investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RPRX = $70.70 (+44.8% from the current price, the stock appears undervalued). Analyst consensus target is RPRX = $51 (+5% upside).
Valuation: RPRX trades at a trailing Price-to-Earnings (P/E) of 26.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.28.
Financials: revenue is $2.4B, +2.1%/yr average growth. Net income is $771M, growing at +838.3%/yr. Net profit margin is 32.4% (strong). Gross margin is 100% (+0.3 pp trend).
Balance sheet: total debt is $9.0B against $6.5B equity (Debt-to-Equity (D/E) ratio 1.38, moderate). Current ratio is 0.97 (tight liquidity). Debt-to-assets is 45.6%. Total assets: $19.6B.
Analyst outlook: 10 / 11 analysts rate RPRX as buy (91%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 37/100 (Fail), Growth 73/100 (Pass), Past 100/100 (Pass), Health 33/100 (Fail), Moat 76/100 (Pass), Future 88/100 (Pass), Income 100/100 (Pass).
